FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

FDA to decide on Roche’s lymphoma drug Lunsumio before year-end

Submitted by admin on July 6, 2022 - 10:49am
Source: 
Pharmaforum
News Tags: 
Roche
Lunsumio
follicular lymphoma
T-cell engager
FDA
priority review
Headline: 
FDA to decide on Roche’s lymphoma drug Lunsumio before year-end
snippet: 

The FDA has granted a priority review to Roche’s T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December.

Do Not Allow Advertisers to Use My Personal information